CG
BCYC

Cutler Group’s Bicycle Therapeutics BCYC Stock Holding History

Cutler Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-800
Closed -$8K – 3616
2023
Q3 		$8K Sell
800
-2,600
-76% -$59.5K ﹤0.01% 2565
2023
Q2 		$12K Buy
3,400
+1,900
+127% +$44.1K ﹤0.01% 2135
2023
Q1 		$12K Buy
1,500
+700
+88% +$17.6K ﹤0.01% 2193
2022
Q4 		$7K Buy
+800
New +$21.5K ﹤0.01% 2910

Other funds holding BCYC

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cutler Group's BCYC Position: Q4 2023 in Review

Cutler Group sold out of Bicycle Therapeutics (BCYC) in Q4 2023, closing a stake of 2,400 shares — an estimated $48K sold.

Cutler Group first reported a position in BCYC in Q3 2021 and held it in 9 quarters. The position peaked at $608K in Q3 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

  • Cutler Group reported no remaining Bicycle Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 2,400 Bicycle Therapeutics shares in Q4 2023, an estimated $48K.
  • Cutler Group first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 9 quarters.
  • Cutler Group's Bicycle Therapeutics position peaked at $608K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.